These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 1155490)

  • 1. Tobramycin in renal impairment.
    Bechtol LD; Black HR
    Am J Med Sci; 1975; 269(3):317-21. PubMed ID: 1155490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients.
    Péchère JC; Dugal R
    J Infect Dis; 1976 Aug; 134 Suppl():S118-24. PubMed ID: 972269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased serum tobramycin concentrations in patient with renal failure.
    Lampasona V; Crass RE; Reines HD
    Clin Pharm; 1983; 2(1):6, 9. PubMed ID: 6883932
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of tobramycin in rats with reduced renal parenchyma and in experimental shock.
    Morávek J; Hatala M; Schück O; Prát V; Liska M; Konícková Z
    J Infect Dis; 1976 Aug; 134 Suppl():S130-2. PubMed ID: 972271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of a two-compartment Bayesian feedback program for therapeutic tobramycin monitoring in the daily clinical use and comparison with a non-Bayesian one-compartment model.
    Kaufmann GR; Vozeh S; Wenk M; Haefeli WE
    Ther Drug Monit; 1998 Apr; 20(2):172-80. PubMed ID: 9558131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tobramycin sulfate elimination in premature infants.
    Arbeter AM; Saccar CL; Eisner S; Sarni E; Yaffe SJ
    J Pediatr; 1983 Jul; 103(1):131-5. PubMed ID: 6864378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin.
    Loirat P; Rohan J; Baillet A; Beaufils F; David R; Chapman A
    N Engl J Med; 1978 Oct; 299(17):915-9. PubMed ID: 692596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum concentrations of tobramycin after intraarticular administration. An experimental study in the rabbit.
    Solgaard S; Frimodt-Møller N; Reimann I
    Acta Orthop Scand; 1983 Jun; 54(3):446-8. PubMed ID: 6190349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients.
    Lockwood WR; Bower JD
    Antimicrob Agents Chemother; 1973 Jan; 3(1):125-9. PubMed ID: 4790568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High tobramycin serum concentrations after tobramycin inhalation in a child with renal failure.
    de Velde F; Emonts M; Verbruggen S; van der Sijs H
    J Antimicrob Chemother; 2014 Nov; 69(11):3163-4. PubMed ID: 25006239
    [No Abstract]   [Full Text] [Related]  

  • 11. [Control of serum levels of tobramycin and amikacin during clinical routine treatment conditions (author's transl)].
    Stark GB; Eiermann T; Langmaack H; Daschner F
    Dtsch Med Wochenschr; 1982 Aug; 107(31-32):1182-4. PubMed ID: 7105995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
    Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of peritoneal dialysis on serum levels of tobramycin and clindamycin.
    Malacoff RF; Finkelstein FO; Andriole VT
    Antimicrob Agents Chemother; 1975 Nov; 8(5):574-80. PubMed ID: 1211913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detectable serum tobramycin concentrations in a patient with renal dysfunction receiving tobramycin by inhalation.
    Langley A; Cottingham L
    Am J Health Syst Pharm; 2011 Aug; 68(15):1385-6. PubMed ID: 21785021
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of plasmapheresis on the removal of tobramycin.
    Kale-Pradhan PB; Dehoorne-Smith ML; Jaworski DA; Hare BL; Provenzano R; Higgins MJ
    Pharmacotherapy; 1995; 15(5):673-6. PubMed ID: 8570442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin therapy of serious infections. Pharmacological aspects and side effects.
    Bruun JN; Eng J; Arnesen AR
    Scand J Infect Dis; 1981; 13(1):59-64. PubMed ID: 7244560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the use of laboratory tests in monitoring tobramycin therapy.
    Pasko MT; Mylotte JM; Boh LE
    Am J Hosp Pharm; 1981 Dec; 38(12):1956-7. PubMed ID: 7325182
    [No Abstract]   [Full Text] [Related]  

  • 18. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospital acquired gram-negative pneumonias: response rate and dosage requirements with individualized tobramycin therapy.
    Cipolle RJ; Seifert RD; Zaske DE; Strate RG
    Ther Drug Monit; 1980; 2(4):359-63. PubMed ID: 7222190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictability of serum concentrations of aminoglycosides after haemodialysis.
    Dijkmans BA; Mattie H
    Eur J Clin Pharmacol; 1987; 33(2):179-83. PubMed ID: 3691608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.